EQUITIES

Robust. Fundamental. Dynamic.

Our teams exercise independent thought with high conviction, resulting in portfolios that we believe are well positioned to address our clients' challenges – all within robust risk control frameworks.

vd-icon_Currency_CashUSD

$217.4bn
Equities Assets Under Management

vd-icon_People_3_Group v3

153
Equities Investment
Professionals

vd-icon_Bulleye_Target v3

20
Average Years’ Financial
Industry Experience

As at 31 March 2025

<span class="notranslate">no data</span>

$217.4bn
Equities Assets Under Management

153
Equities Investment
Professionals

20
Average Years’ Financial
Industry Experience

As at 31 March 2025

We measure success by a single factor: client outcomes. As a pure asset manager, our sole mission is to deliver consistent long-term risk-adjusted returns that exceed our benchmarks and peers, regardless of the prevailing investment landscape.

Featured strategies

Global Life Sciences

By understanding the science and business of health care, our experienced team seeks to invest in companies addressing unmet medical needs or improving efficiencies.

Biotechnology Innovation

A biotechnology strategy that seeks to leverage a disciplined approach to identify compelling opportunities across the biotech landscape in both public and private investments

Global Technology Leaders

A global approach to investing in technology companies from a highly experienced team

Insights

Quick View: US-Japan trade deal reshapes Japan’s investment outlook

Implications of the US-Japan tariff deal for Japanese stocks.

How AI is creating new opportunities in healthcare

As AI makes inroads into healthcare, opportunities for patients and investors grow.

Janus Henderson Live: Technology and human resilience in New York

Janus Henderson’s ‘Partnerships for a Brighter Future’ event in New York discussed AI and bionic enhancements that can support human resilience.